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Abstract: Malignant pleural mesothelioma (MPM) is a rare tumor that is challenging to 
control. Despite some benefit from using the multimodality-approach (surgery, combination 
chemotherapy and radiation), survival remains poor. However, current research produced a list 
of potential therapies. Here, we summarize significant new preclinical and early clinical devel-
opments in treatment of MPM, which include mesothelin specific antibody and toxin therapies, 
interleukin-4 (IL-4) receptor toxins, dendritic cell vaccines, immune checkpoint inhibitors, 
and gene-based therapies. In addition, several local modalities such as photodynamic therapy, 
postoperative lavage using betadine, and cryotherapy for local recurrence, have also shown to 
be effective for local control of disease.
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Introduction
Malignant pleural mesothelioma (MPM) is a rare asbestos-induced malignancy with 
an estimated incidence of approximately 2,180 new cases diagnosed in the United 
States in 2013.1 Approximately 30% of US cases are diagnosed among veterans, and 
20% are seen in women. Worldwide, nearly 80% of mesothelioma deaths occur in ten 
countries, with the United Kingdom, United States, and Japan being in the top three.2 
While peak incidence of MPM in the US has been reached, worldwide it is expected 
to continue to increase over the next several decades.3 Median survival ranges from 
9–18 months and correlates with stage.4,5
Currently established therapy
Chemotherapy
Pemetrexed and cisplatin combination therapy was established as a standard treatment 
for mesothelioma patients who are not surgical candidates after a landmark multicenter 
randomized Phase III trial of 456 patients.6 The trial demonstrated a nearly 3-month 
survival benefit, with median survival of 12.1 months versus 9.3 months for patients 
treated with cisplatin alone. Tumor response was seen in 41.3% of the 226 pemetrexed 
and cisplatin treated patients and 16.7% of the 222 patients receiving cisplatin alone.
Surgical resection
The theoretical goal of surgical resection is to achieve complete tumor removal (R0 
resection), which in reality is virtually impossible. A more realistic goal is to achieve 
an R1 resection with only microscopic residual disease.
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While the Mesothelioma And Radical Surgery (MARS) 
feasibility trial showed that few patients qualified for surgery 
and the outcomes did not support extrapleural pneumonec-
tomy (EPP),7 surgery is offered to select patients in high 
volume centers with specific interest in mesothelioma, and 
it may offer a survival advantage. EPP was formerly thought 
to produce better survival than pleurectomy and decortica-
tion (P/D) but as more evidence accumulates P/D actually 
may offer a better survival.5,8 Indirect evidence supporting 
this comes from work by Flores et al,5 who observed overall 
survival of only 10.2 months in patients who did not undergo 
any surgery and 14.0–15.8 months in those who underwent 
resection.
Radiation
Radiation has been used for either gross tumor (palliative 
intent) or for adjuvant local control in the postoperative 
setting in an attempt to control the residual microscopic 
disease that is nearly universally present following any 
surgical resection. The ability to administer effective doses 
of radiation to the large surface area of the pleural space, 
particularly following P/D with the lung in place, is quite 
challenging. Consequently, the broadest application of 
postoperative radiation has been in patients following EPP 
since the ipsilateral lung is removed. However, the risk for 
toxicity to the adjacent organs (heart, spinal cord and liver, 
esophagus) remains. Despite the theoretically lower risk of 
pulmonary toxicity, radiation following EPP was associated 
with a nearly 20% incidence of severe pneumonitis in the 
contralateral lung in at least one study.7
Several groups have described use of radiation in 
patients after ipsilateral lung preservation with P/D with an 
 acceptable toxicity profile (summarized in Table 1). Thus 
newer techniques, such as tomotherapy,9,10 which are able 
to deliver a circumferential focused radiation field closely 
following the contour of the chest wall and lung periphery, 
potentially limiting toxicity to the lung parenchyma, allow 
postoperative radiation doses after P/D to be nearly the same 
as after EPP: 45–50 centigray.11–14
The role of preoperative radiation was evaluated in the Sur-
gery for Mesothelioma After Radiation Therapy (“SMART”) 
trial, which was a feasibility study only.15 Five fractions of 
radiation were given to the hemithorax 1 week prior to EPP, 
with no acute pulmonary toxicities noted in 26 patients but 
with half the patients developing postoperative complica-
tions. Although survival data was reported and an enhanced 
immune response speculated, more studies are needed before 
any conclusions can be made regarding impact.
Multimodality therapy
Currently, specialized mesothelioma centers employ multi-
modality approaches, including surgical resection, chemo-
therapy, and radiation, with survival in excess of 20 months 
depending on stage.5 Reports from the Society of Thoracic 
Surgeons Database16 and the European Organisation for 
Research and Treatment of Cancer strongly suggest that 
multimodality therapy in highly specialized centers is associ-
ated with less morbidity and mortality.17
Hyperthermic intraoperative 
chemotherapy
Experimental data suggests that heating chemotherapeutic 
agents increases entry into tumor cells. Clinically, most data 
come from Phase I–II studies evaluating systemic toxicity of 
intrapleural drug (most commonly cisplatin) administration 
in highly selected patients.18 Median survival of patients 
Table 1 Studies evaluating toxicity of radiation in intact lung
Study N Radiation dose Pulmonary toxicity Median survival, 
months
Overall 
survival
Minatel et al11,12 28a 5,000 cGy in 25 fractions 17.8%: 
Grade 2 in 3 patients 
Grade 3 in 2 patients
33 2 years – 70% 
3 years – 49%
Rosenzweig et al13 36b 4,680 cGy (range  
4,140–145,040 cGy)
20%: 
Grade 3 in 5 patients 
Grade 4–5 in 2 patients
26 1 year – 75%; 
2 years – 53%
Bolukbas et al14 29c 5,040 cGy No report of radiation  
toxicity specifically; note  
that it was well tolerated
30 1 year – 69% 
2 years – 50% 
3 years – 31%
Cho et al15 25 2,500 cGy in 5 fractions +  
500 cGy boost
None at 1 week when  
patients underwent ePP
NR 3 years – 58%
Notes: aTwenty patients underwent pleurectomy/decortication and eight patients had biopsy only prior to radiation. Survival is reported for 20 patients who underwent 
pleurectomy/decortication and radiation. bTwenty patients underwent pleurectomy and decortication and 16 patients had no surgery prior to radiation. cOnly five patients 
underwent 5,040 cGy of radiation; 29 additional patients received 2,100 cGy in three fractions to the incision and chest tube sites.
Abbreviations: cGy, centigray; ePP, extrapleural pneumonectomy; N, number of patients; NR, not reported.
Cancer Management and Research 2015:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
53
New and emerging therapeutic options for mesothelioma
treated with this methodology ranges from 9–20 months 
and there may be a trend toward prolonged disease-free 
intervals in those treated with higher doses.19 A retrospective 
review by Sugarbaker et al20 reported a longer survival and 
progression free interval in early-stage patients treated with 
hyperthermic intraoperative chemotherapy. However, lack 
of randomized trials raises a question whether this method 
represents significant benefit.
New and future therapies
Successful treatment of mesothelioma will depend on 
improved understanding of the biology of mesothelioma.21 
Clinicaltrials.gov listed 192 registered trials (Phases I–III) 
worldwide evaluating multiple therapeutic approaches in a 
variety of settings. A large number of these trials focus on 
novel agents, which have arisen primarily from our expanded 
knowledge of molecular signaling and immune response. 
Several classes of targeted therapies have emerged from 
preclinical work and are being evaluated. These focus on 
following broad mechanisms:
•	 Tyrosine kinase inhibitors
•	 Antibody conjugated toxins
•	 Immune checkpoint inhibitors
•	 Gene therapy
•	 Tumor vaccines.
Tyrosine kinase inhibitors
epidermal growth factor receptor
Epidermal growth factor receptor (EGFR) is expressed by a 
variety of epithelial malignancies, and activation of the path-
way interferes with apoptosis, uncontrolled cell proliferation, 
and agiogenesis.22 EGFR overexpression in mesothelioma 
samples was reported by several authors,23–25 and inhibition 
of EGFR-dependent signaling pathway in mesothelioma cell 
lines also leads to decreased cell survival.22
Several clinical trials based on these findings have been 
conducted but, disappointingly, did not show improved 
survival (summarized in Table 2). Furthermore, the level 
of EGFR overexpression did not correlate with clinical 
outcomes.26 Additional data showed that mutations found 
in patients with other cancers may not be the same in 
malignant mesothelioma tumors,25 or alternatively the 
frequency of mutation may be too low in mesothelioma 
patients,24 resulting in the lack of clinical response in non-
selected patients.
vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) is produced 
by a variety of tumors, including pleural mesothelioma, 
and stimulates neovascularization of tumors30 in addition 
to normal angiogenesis. Elevated levels of VEGF and its 
receptor have been detected by immunohistochemistry in the 
tissue specimens of patients with mesothelioma31,32 and as 
free circulating molecules.33 Higher levels may be reflective 
of more-advanced disease and were associated with shorter 
survival in both studies. In vitro studies demonstrated that 
increased mesothelioma cell proliferation occurred when 
treated with VEGF and that significant inhibition of cell 
growth occurred when this pathway was blocked.34 As a 
result, interference with this pathway potentially could lead 
to successful therapy.
VEGF antibody binds the receptor and inhibits its 
 activation.30 Bevacizumab has been approved to treat 
advanced colorectal, renal cell, and gastrointestinal stromal 
cancers. Numerous clinical trials (Table 3) evaluated the 
effect of VEGF inhibitors alone and in combination 
with chemotherapy in MPM. Unfortunately, the results 
of these trials have been disappointing. Overall survival 
ranged from 4–15 months and this difference was likely 
due to the highly variable design of individual trials. For 
instance, several trials required failure of first-line therapy 
Table 2 Summary of published clinical trials evaluating blocking effects of eGFR
Agent/author Study design N Median survival 
(months)
Overall 1-year 
survival
Response and comments
Gefitinib
Govindan et al27
Phase ii 
No prior systemic chemo
43 6.8a 32% 1 complete response; 1 partial response; 
eGFR expression does not predict 
response
Erlotinib
Garland et al28
Phase ii 
No prior systemic chemo
63 10 43% None had response; no correlation 
between eGFR expression and response
Erlotinib and  
bevacizumab
Jackman et al29
Phase ii 
Prior systemic chemo
24 5.8 24% No responses observed; 12 with stable 
disease
Note: ain this study, survival varied from 8.1 months in patients with high eGFR levels and 3.6 months in patients with low eGFR expression.
Abbreviations: eGFR, epidermal growth factor receptor; N, number of patients.
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before initiation of VEGF antibody treatment, while other 
trials allowed it to be given as first-line therapy. The only 
study35 with a truly prospective randomized allocation to 
either standard chemotherapy (cisplatin and pemetrexed) 
or standard chemotherapy with addition of bevacizumab 
showed no difference in disease progression or overall 
survival.
Toxicities of TKIs were usually well tolerated, and 
only one trial concluded that it was excessive and the 
agent should not be used.36 Table 4 summarizes ongoing 
trials, but results have been uniformly disappointing and 
it is unclear whether these agents will assume significant 
clinical roles.
Additional molecular targets
In addition to a large number of kinase inhibitors, several 
other specific molecular agents are being investigated. Some 
of these agents influence a common pathway downstream 
of the EGFR pathway, while other exert action via different 
mechanisms. For example, histone deacetylase inhibitors 
(belinostat and vorinostat) exert their action through modi-
fication of histones, thus controlling gene transcription.37 
A clinical trial evaluating belinostat in 13 patients was not 
promising, having found belinostat to be ineffective as a 
single second-line regimen in patients with MPM.38 As 
a result, a planned trial of vorinostat combined with chemo-
therapy has been halted.
Bortezomib is a selective inhibitor that acts via downregu-
lation of nuclear factor-κB and promotes apoptosis. Despite 
having favorable preclinical results, bortezomib was associ-
ated with significant toxicity and lack of expected response 
in early clinical trials.39 Additional investigational strategies 
evaluated the role of arginine depletion, effect of everolimus, 
role of HSP90 inhibitors, ranpirnase, and more. These active 
trials are summarized in Table 5.
Therapy targeting cell-surface receptors
Mesothelin
Mesothelin is a 40 kDa cell-surface differentiation glyco-
sylphosphatidylinositol-anchored glycoprotein present on 
normal mesothelial cells and overexpressed on the surface 
of mesothelioma as well as ovarian and pancreatic adeno-
carcinoma cells. It is shed into pleural fluid and released 
into the serum in 71% of mesothelioma, 67% of ovarian, 
and nearly all pancreatic cancer patients, but also in normal 
volunteers.40,41 Mesothelin overexpression, occurring more 
prominently on epithelioid tumors, may serve to alter cell 
adhesion and/or invasion.42D
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an antigen and stimulates activation of T-cells upon exposure 
to CRS-207.47 A Phase I trial, including five mesothelioma 
patients, determined the maximum tolerated dose to be 
1×109 colony-forming units with a favorable safety profile.47 
Mesothelin-specific CD8+ T-cell response was induced in six 
out of ten evaluable subjects but did not correlate with clinical 
response. Currently, an ongoing Phase I trial (Clinicaltrials.gov 
NCT01675765) is evaluating Listeria vaccine in combination 
with chemotherapy in patients with MPM.
SS1P immunotoxin
SS1P is an immunotoxin consisting of an antimesothelin 
antibody variable fragment linked to a cytotoxic fragment 
of Pseudomonas exotoxin A. A Phase I trial including 
16 patients with mesothelioma showed that SS1P was well 
tolerated up to 25 µg/kg/day × 10 days with modest clinical 
activity and minor responses, and that two mesothelioma 
patients had symptomatic improvement.48 Continuous infu-
sion showed no advantage over bolus dosing.49 A significant 
number of patients developed neutralizing antibodies after 
one cycle and were not able to receive additional therapy. In 
a subsequent study, Hassan et al50 attempted to abrogate the 
production of neutralizing antibodies by inducing an immu-
nosuppressive state with pentostatin and cyclophosphamide. 
Interestingly, three of ten patients achieved a partial response, 
but two patients (one with stable and one with progressive 
disease) experienced dramatic tumor reduction with subse-
quent chemotherapy. Durable responses were correlated with 
high serum SS1P levels following the second dose and with 
multiple doses of therapy. The median overall survival was 8.8 
months with a median follow-up of 12.7 months.50 A Phase 
I trial (Clinicaltrials.gov NCT01445392) of SS1P infusion 
Table 4 Summary of ongoing clinical trials evaluating various kinase inhibitors
Therapy Number of trials Agent Trial ID Phase
veGFR kinase inhibitors 8 Bevacizumab 
Bevacizumab 
Nintedanib 
Dovitinib 
Cediranib 
Axitinib 
Dasatinib 
imatinib
NCT00651456 
NCT00604461a 
NCT01907100 
NCT01769547 
NCT01064648 
NCT01211275 
NCT00652574 
NCT00402766
ii 
ii 
ii 
i–ii 
i–ii 
i 
i
eGFR kinase inhibitor 1 Cetuximab NCT00996567 ii
Other kinase inhibitors 3 PF-03446962  
(anti-ALK antibody) 
Defactinib (FAK) 
Defactinib (FAK)
NCT01486368 
 
NCT01870609 
NCT02004028
ii 
 
ii 
ii
Note: aTrial was terminated.
Abbreviations: ALK, activin receptor-like kinase; EGFR, epidermal growth factor receptor; ID, identification number; VEGFR, vascular endothelial growth factor receptor; 
FAK, focal adhesion kinase.
Antimesothelin antibodies
MORAb-009 (amatuximab) is a chimeric IgG1kappa 
murine monoclonal antibody with high affinity for human 
 mesothelin.43 Following receptor binding, this highly 
specific antibody is rapidly internalized43 and induces 
 antibody-dependent cellular cytotoxicity and inhibits cel-
lular adhesions via interaction with MUC16 in a receptor 
density-dependent manner.44 Preclinical studies in nude mice 
suggested that MORAb-009 combined with chemotherapy 
(gemcitabine or paclitaxel) was more effective than either 
chemotherapy agent alone.43 An initial Phase I clinical trial 
demonstrated that MORab-009 is well tolerated, with a 
maximum tolerated dose of 200 mg/m2, and that eleven of 
24 patients exhibited stable disease.45 A Phase II clinical trial 
(Clinicaltrials.gov NCT00738582) evaluating the combina-
tion of MORab-009 with cisplatin and pemetrexed in patients 
with pleural mesothelioma has completed recruitment but 
results have not been published.
BAY 94-9343 (anetuman ravtansine) is a fully human 
antimesothelin antibody coupled via a reducible disulfide 
linker to DM4, a microtubule-targeting toxophore that shows 
highly selective cytotoxicity against cells with high levels of 
mesothelin expression with an additional potent bystander 
effect.46 Preclinical studies showed a dose-dependent and 
receptor-dependent 94% reduction of tumor growth with BAY 
94-9343 compared to 70% with cisplatin and pemetrexed che-
motherapy.46 This drug is now being evaluated in an ongoing 
Phase I trial (Clinicaltrials.gov NCT01439152).
CRS-207 vaccine
CRS-207 is a genetically modified Listeria monocytogenes 
attenuated vaccine expressing mesothelin. Mesothelin acts as 
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. combined with chemotherapy (cisplatin and pemetrexed) is 
closed to recruitment and awaiting data analysis.
interleukin-4 receptor
Interleukin-4 (IL-4) acts as a growth factor for T helper 2 cells 
and induces immunoglobulin class switch in allergic responses. 
Several studies showed that in addition to some subsets of 
immune cells, high affinity IL-4 receptors also are present 
on a variety of human tumors including  mesothelioma.51–53 
Clinically, high levels of IL-4 receptor expression have been 
shown on fresh human mesothelioma specimens and correlated 
with a worse outcome.54,55  Furthermore, higher IL-4 receptor 
expression levels were noted in biphasic and sarcomatoid 
histology specimens, which have a significantly worse prog-
nosis compared to epitheloid histology.55 These IL-4 receptors, 
therefore, represent potential clinical targets.
Beseth et al54 showed that a circularly permuted recombi-
nant IL-4 toxin IL-4(38–37)-PE38KDEL or cpIL-4-PE that 
contains amino acids 38–129 of IL-4 fused by a peptide linker 
to amino acids 1–37, which are in turn fused to amino acids 
353–364 and 381–608 of Pseudomonas exotoxin. KDEL 
at positions 609–612 allows it reversibly bind to mesothe-
lioma cells and inhibit protein synthesis in vitro. In a human 
mesothelioma xenograph nude mouse model, intratumoral 
injection of IL-4(38–37)-PE38KDEL significantly reduced 
tumor volumes in a dose-dependent manner compared to 
the control and IL-4-treated mice.54 Furthermore, survival 
of similarly treated mice was significantly prolonged to a 
median of .102 days from 28 days in the two control groups 
(P,0.0001). Yang et al56 reported similar findings with a 
hybrid IL-4Rα–lytic peptide designed by the group. Although 
a pancreatic model was used, the results could be applied to 
mesothelioma. Phase I trials are being planned but have not 
yet started to accrue patients.
immune checkpoint inhibitors
Cytotoxic T lymphocyte antigen-4
Immune checkpoints are pathways that dampen inflam-
matory responses and mediate immune tolerance toward 
normal tissue. Because most immune checkpoints are initi-
ated by ligand–receptor interactions, they can be readily 
blocked by antagonist antibodies or recombinant forms of 
cognate ligands/receptors. Cytotoxic T lymphocyte antigen-4 
 (CTLA-4) is vital for maintaining host immune tolerance 
to established tumors.57 The CTLA-4 receptor sequesters 
CD80 and CD86 immune costimulatory signals provided 
by antigen-presenting cells, thus raising the activation 
threshold for T lymphocytes. Systemic administration of 
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Table 6 Clinical trials involving gene therapy in treatment of MPM
Study Type of therapy N Survival, months Comments
Sterman  
et al64
intrapleural adenovirus 
Herpes simplex suicide gene
34: 
21 high dose 
13 low dose
MS – 15 
MS – 10
Neutralizing antibody developed 
Suggests that response may be due to 
immunologic stimulation by tumor antigens
Sterman  
et al66
intrapleural adenoviral vector  
with IFNβ gene ×1 dose
8 NR 
(3 patients alive)
Activation of NK cells and increase in levels 
of anti-mesothelin antibody in some patients
Sterman  
et al67
intrapleural adenoviral vector  
with IFNβ gene ×2 doses
10 OS .18 monthsa Neutralizing antibody production noted 
with lower subsequent pleural iFN levels
Sterman  
et al68
intrapleural adenoviral vector  
with IFNα2b gene ×2 doses
9 NR 
(OS ranged from 1–22  
months with 3 patients alive)
Strong activation of NK cells
Note: aincludes seven additional patients with malignant effusions from ovarian, breast, or lung carcinomas.
Abbreviations: iFN, interferon; MPM, malignant pleural mesothelioma; MS, median survival; N, number of patients; NK, natural killer; NR, not reported; OS, overall survival.
CTLA-4 blocking antibody as monotherapy or combined 
with therapeutic tumor-cell vaccination induced regression 
of established melanoma and colon tumors in mice.57,58
A Phase II trial evaluating anti-CTLA-4 antibody (tremeli-
mumab) in 29 patients with chemotherapy-resistant advanced 
mesothelioma (28 pleural and 1 peritoneal) was recently 
reported by Calabrò et al.59 Objective clinical responses 
were observed in only two of 29 patients. However, disease 
stabilization was noted in nine patients (31%), all with epi-
thelioid histology. Overall survival rates were 48% at 1 year 
and 37% at 2 years. Currently, there are two active clinical 
trials investigating the administration of  tremelimumab 
in patients with pleural mesothelioma  (ClinicalTrials.gov 
NCT01655888 and NCT01843374).
Programmed death receptor-1
Programmed death receptor is found on the surface of T-cells 
and its stimulation leads to T-cell deactivation, thus allowing 
escape from the immune system surveillance in the presence of 
otherwise antigenic substrate.60 Activation of this receptor occurs 
by a programmed death ligand 1 (PD-L1), which exists within 
the tumor microenvironment on the surface of tumor cells.61
Currie et al60 demonstrated PD-L1 to be present on murine 
mesothelioma cells in vivo. Interestingly, upregulation of PD-L1 
expression occurred in response to increased concentrations of 
interferon (IFN)-γ and T-cells in tumor draining lymph nodes, 
supporting the hypothesis that this is an important pathway 
of tumor-mediated local immunosuppression.60 The effect of 
PD-L1 blockade on different subpopulations of T-cells pro-
duced opposing effects on tumor progression and suggested 
that tumor-derived immune suppression is mediated by specific 
subsets of T-cells. Mansfield et al62 noted that PD-L1 expression 
occurred in approximately 40% of 106 mesothelioma specimens 
(all sarcomatoid tumors) and higher expression was correlated 
with worse prognosis (5.0 months versus 14.5 months).
Several trials are currently evaluating role of inhibition 
in this pathway using different agents (lambrolizumab and 
nivolumab) in cancers other then MPM.
Gene therapy
Multiple genetic abnormalities have been identified in meso-
thelioma, and a variety of genetic manipulation strategies 
have been employed in preclinical studies.63 Several types 
of gene therapies have shown particular promise and are 
discussed below.
Suicide gene therapy
This approach utilizes engineered viruses that deliver 
transgenes encoding enzymes that metabolize prodrugs 
into toxic metabolites capable of killing tumor cells. Mul-
tiple viral vectors have been studied. A clinical trial of 
intrapleural Adenovirus herpes simplex thymidine kinase/
ganciclovir64 enrolled 34 patients and reported minimal 
morbidity and a dose-dependent median survival as high 
as 15 months at the highest viral titers. Some patients 
experienced prolonged survival, suggesting induction of 
antitumor immunity in addition to the acute viral-mediated 
cytotoxicity.64
Cytokine gene therapy
Another strategy involves administration of viral vectors 
encoding specific cytokine gene(s) that may exert a direct 
cytotoxic effect on tumor cells or may alter the immunologic 
response(s) to the tumor. Although early trials of direct 
intrapleural administration of interleukin-2 (IL-2) showed a 
nearly 50% response rate and a 28-month median survival in 
responders,65 subsequent interest has centered on gene therapy 
with IFN, which play a key role in activation of the immune 
system and have direct antitumor cytotoxic/cytostatic effects. 
Several clinical trials (summarized in Table 6) evaluated 
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Table 8 Active trials investigating vaccine-based strategy
Vaccine antigen Additional therapies combined  
with vaccine
Trial ID Sponsor
wT-1 (randomized) GM-CSF NCT01265433 Memorial Sloan-Kettering Cancer Center
wT-1 GM-CSF NCT01890980 MD Anderson Cancer Center
5T4 tumor-associated antigen expressed  
by modified vaccinia virus (TroVax)
Chemotherapy NCT01569919 wales Cancer Trials
PA-1-STK compound  
– modified ovarian carcinoma vaccine
Cancyclovir NCT00006216 University of Louisiana, NCi
Allogeneic tumor cella Cyclophosphamide and celecoxib NCT 01143545 NCi
Mesothelin (CRS-207) Chemotherapy NCT01675765 Aduro BioTech inc
Note: aincludes malignant mesothelioma, lung, esophageal, and thymic cancers.
Abbreviations: GM-CSF, granulocyte/macrophage colony-stimulating factor; ID, identification number; NCI, National Cancer Institute; WT-1, Wilm’s tumor-1.
Table 7 Current investigations in gene therapy
Gene therapies Agent Route of  
administration
Status Study ID Sponsor
Cytokine-based interferon intrapleural Recruiting NCT01212367 University of Pennsylvania/NCi
interferon with chemotherapy intrapleural Unknown NCT01119664 University of Pennsylvania
Suicide gene Herpes simplex virus intrapleural Recruiting NCT01721018 virttu Biologics Limited
Measles virus intrapleural Recruiting NCT01503177 Mayo Clinic/NCi
Autologous modified  
T-cells with receptor to:
Fibroblast activation protein intrapleural Not yet recruiting NCT01722149 University of Zurich
Mesothelin intravenous Recruiting NCT01355965 University of Pennsylvania
Abbreviations: ID, identification number; NCI, National Cancer Institute.
adenoviral-mediated IFN (α and β) therapy in patients with 
MPM.66–68 Survival ranged from 1–22 months with some long-
term survival, but neutralizing antibodies did limit ability to 
administer repeated treatments.
Gene-modified lymphocytes
Genetically engineered autologous T lymphocytes may 
increase antigen recognition or alter the immunosuppressive 
tumor microenvironment through production of cytokines.69 
Carpenito et al70 reported that antimesothelin-engineered 
T-cells mediated specific cytolysis of mesothelin-expressing 
cells and produced significant tumor regression in animals. 
Fibroblast activating protein71 and chemokine receptor-272 
also have been evaluated in vitro as possible additional can-
didates for T-cell genetic modifications.
Currently ongoing clinical trials involving gene therapies 
are summarized in Table 7.
immunotherapy and vaccines
Dendritic cell vaccines
Successful cancer immunotherapy requires effective 
antigen presentation. Antigen-exposed autologous den-
dritic cells remain the most potent antigen presenting 
cell.  Preclinical in vitro and in vivo data supports the 
use of dendritic cell vaccines as a valuable strategy in 
mesothelioma.73  Calretinin, mesothelin, and Wilm’s 
tumor-1 have been used as candidate antigens, and mea-
surable specific immune responses were shown to these 
antigens in early clinical trials, although no responses 
were seen.74,75 In a pilot Phase I study, Hegmans et al76 
exposed autologous dendritic cells ex vivo to autologous 
tumor antigens purified from pleural effusions or biopsy 
samples. This vaccine strategy was well tolerated and pro-
duced three partial responses with overall median survival 
of 19 months, which is encouraging.
Currently, several manufactured mesothelioma vaccines 
are being evaluated in Phase I–II clinical trials and are sum-
marized in Table 8.
Direct physical cytotoxic therapies
Photodynamic therapy
Photodynamic therapy (PDT) was originally investigated 
by Pass at the National Cancer Institute in the 1980s.77 PDT 
recently has been used by Friedberg et al78 following a metic-
ulous P/D. In a Phase I–II experience, the median disease-free 
progression was 15 months and the overall survival was over 
40 months.78 Due to this encouraging data, a Phase II trial 
(NCT NCT02153229) is ongoing and a randomized Phase 
III trial now is being planned, as is further investigation into 
the basic science of PDT (NCT02106559).
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Heated therapy
Sugarbaker18–20 has advocated in favor of intraoperative 
hyperthermic chemotherapy; however, evidence supporting 
the use of hyperthermia is quite limited. No controlled trials 
exist and a recent report by Cameron and Hou79 suggested that 
temperatures required for a clinically meaningful effect were 
43°C-45°C, far above those currently used at most centers, 
and that hyperthermia and chemotherapy were additive and 
not synergistic.
iodine–povidone (betadine) lavage
A Phase I–II trial of intraoperative hyperthermic (41°C) 
iodine–povidone lavage following surgery (either P/D or 
EPP) was recently reported by Lang-Lazdunski et al.80 
Mechanism of action is likely generation of reactive oxygen 
intermediate species leading to cellular necrosis.81 Although 
the treatment was tolerated well and the surgical outcomes 
were acceptable, convincing evidence of efficacy is still 
lacking.
Cryotherapy
Cryotherapy for the treatment of cancer has been used 
for decades.82–85 Abtin et al86 recently reported the use of 
percutaneous cryoablation in 24 mesothelioma patients for 
control of limited recurrent local disease following P/D. 
The treatment was well tolerated, had a .90% control rate, 
and was associated with a median survival of 11.4 months 
following first therapy (36.1 months following surgery). 
Cryotherapy also may enhance immune responses through 
enhanced natural killer cell activity, T-cell responses and 
systemic IFN production.87 In an animal model of prostate 
cancer, tumor cryotherapy with simultaneous anti-CTLA-4 
immunotherapy produced enhanced immune-mediated 
protection against tumor rechallenge at both primary and 
distant tumor sites.88
Summary
MPM remains a challenging tumor to control. Despite 
some benef it from surgery and combination chemo-
therapy (cisplatin/pemetrexed), survival remains poor.6 
However, the list of potential new therapies is long and 
the number of clinical trials is impressive (nearly 200). 
With all the ongoing research, progress is only a mat-
ter of time. Although the low prevalence of this disease 
makes enrollment in clinical trials challenging, more than 
1,000 patients over the last decade have participated in 
the clinical trials covered by this review. In the future, it 
is critical that  clinicians treat this disease with equipoise 
and that patients be placed in randomized prospective 
clinical trials in order to truly determine optimal therapy 
for these patients.
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